Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunex -- Ignore unavailable to you. Want to Upgrade?

To: James Baker who wrote (319)	5/12/1999 2:09:00 PM
From: Roger Cranwill	Read Replies (4) \| Respond to of 656

Jeez-What is this, people? Immunex was the story of the day yesterday, closing up 35+ points, and not a word about it on this board? (Ho Hum, only 35 points, it could have done better)-how?! The fact that (with FDA approval) Enbrel will increase its potential market by 2+million people is astounding! Also, as a pharmacist, I believe the asthma drug Immunex has in the pipeline may actually overshadow Enbrel's sales when brought to market (with FDA approval, of course). Once a week dosing for asthma would, in my opinion, corner this segment of a HUGE patient-base... What do you think? Anyone? Anyone?